FcγRIIA activation is key for platelet aggregation in response to bacteria, and depends on IgG and α IIbβ3 engagement. PF4 binds to bacteria and reduces the lag time for platelet aggregation.
Introduction
Despite an increasingly recognized role for platelets in immunity, [1] [2] [3] [4] our knowledge of the molecular events that control platelet-bacteria interactions is rudimentary.
Moreover, there is increasing evidence that acute and chronic infections play a role in the development and progression of cardiovascular and related diseases including infective endocarditis, atherothrombosis and sepsis, [5] [6] [7] [8] [9] and that this may involve direct activation of platelets by bacteria. Platelet activation can be responsible for the most severe sequelae of bacterial infection. For example, infective endocarditis is a focal infection of the heart valves characterized by inflammation that is associated with the build-up of platelets, fibrin and bacteria on the valves of the heart. 10 The biggest risk for patients is embolization of the clots to the brain causing multiple small infarcts. Another life threatening disease is sepsis and sepsis associated disseminated coagulopathy during which clotting factors and platelets are consumed by disseminated microvascular thrombosis. The bacterial species that are more frequently involved in these conditions include viridans group streptococci (Streptococcus sanguinis (S. sanguinis),
Streptococcus gordonii (S. gordonii) and Streptococcus oralis (S. oralis)) and
Staphylococcus aureus (S. aureus) 11, 12 in infective endocarditis, or Streptococcus pneumoniae (S. pneumoniae) in sepsis. Strains of these species have been shown to stimulate platelet aggregation and secretion directly.
13-17
Bacteria can interact with platelets through a variety of mechanisms. 4 Bacteria express proteins that recognize platelet receptors. For example, oral streptococci express a family of highly glycosylated serine rich proteins that bind to platelet GPIbα: S.
sanguinis expresses serine rich protein A (SrpA) 16 ; S. gordonii, hemagglutinin salivary antigen (Hsa) 17 ; and S. oralis whose GPIbα ligand has yet to be identified. 15 In addition, S. gordonii expresses platelet adherence protein A (PadA) 18 and S. aureus expresses Bacteria-induced platelet aggregation, as measured by Born-aggregometry, is associated with a characteristic lag time that varies from seconds to several minutes and is then followed by full aggregation. In contrast, most platelet agonists cause rapid activation, which can give rise to partial aggregation when low concentrations of agonist are used.
This suggests that bacteria have a unique positive feedback mechanism that gives rise to an 'all-or-nothing' response.
FcγRIIA has been shown to play a role in mediating activation to several strains of bacteria. 4, 15 FcγRIIA is a low affinity receptor for the In the present study, we have investigated the hypothesis that bacterial activation of platelets is mediated through a common pathway that is dependent on FcγRIIA and that this pathway is reinforced during platelet activation possibly through secretion of PF4 and other secondary mediators.
Methods

Reagents
Fibrinogen was from Calbiochem (Merck Millipore, Nottingham, UK All strains were cultured anaerobically at 37°C overnight and prepared as described.
13,15
Washed bacteria were adjusted in PBS to an optical density of 1.6 at a wavelength of 600 nm corresponding to the following concentrations: S. sanguinis 133-79, 6x10 8 colony-forming units (CFU)/mL; S. aureus Newman, 1x10 9 CFU/mL; S. gordonii DL1, 3x10 9 CFU/mL, S. oralis CR834, 4x10 9 CFU/mL; S. pneumoniae IO1196, 7x10 8 CFU/mL. Bacteria were used at a ten-fold dilution in aggregation assays. 
Human platelets
Aggregation and ATP secretion
Platelet aggregation was assessed by light transmission in a PAP-4 aggregometer for up to 30 min. Time-matched controls were run alongside. Stimulation by cross-linking of FcγRIIA was performed by preincubation of platelets for 3 min with mAb IV.3 (4 μ g/mL) followed by anti-mouse IgG F(ab') 2 (30 μ g/mL). ATP release was assessed at the end of the recording using a luciferin-luciferase based assay.
13
PF4 secretion
Aggregation reactions were stopped at the end of the experiment by addition of PGI 2 (4μM) and centrifuged at 1500g for 10 min at room temperature. Plasma supernatants were obtained for PF4 measurement by ELISA (Human CXCL4/PF4 Elisa, R&D Systems, Abingdon, UK). 
PF4 binding to bacteria
PF4 binding to bacteria was measured using biotinylated human PF4 (20 μ g/mL) as previously described. 25 Where indicated, bacteria-PF4 incubations were performed in the presence of 46% pooled plasma from healthy donors.
Statistical analysis
Statistical analysis was performed using GraphPad (Prism). Data are presented as the mean ± standard deviation (SD) unless otherwise stated, and comparisons between mean values were performed using Student's t-test, or ANOVA when multiple samples were compared. P<0.05 (two-tailed) was considered significant.
Results
Bacteria stimulate platelet aggregation and secretion via FcγRIIA and αIIbβ3
The strains of the five bacterial species used in this study are known to induce 'all-ornothing' aggregation of platelets following a lag time that decreases with increasing
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 9 concentrations of bacteria, as illustrated for two of them in Figure S1A and S1B. This is in contrast to the immediate onset and partial response induced by crosslinking of an intermediate concentration of mAb IV.3 to induce clustering of FcγRIIA, 37 with full aggregation observed in response to a higher concentration ( Figure S1C ).
In this study, bacteria were used at concentrations that have been optimized previously.
All strains stimulated maximal platelet aggregation but with a strain-specific delay that varied from 120 to 900 sec ( Figure 1A ). In all cases, aggregation was associated with robust secretion of dense and α−granules as shown by measurement of ATP and PF4, respectively, that is similar in magnitude to that induced by FcγRIIA clustering ( Figure   1B and 1C). Consistent with previous studies 13- 17 , aggregation was blocked to all stimuli in the presence of the αIIbβ3 antagonist Integrilin (eptifibatide) ( Figure S2A ).
Unexpectedly, however, dense and α-granule secretion was also inhibited by Integrilin demonstrating that secretion is dependent on αIIbβ3 engagement ( Several studies have reported a critical role for IgG and FcγRIIA in platelet activation by several of the bacteria used in this study. 13, 15, 16, 38, 39 In line with this, we demonstrate that mAb IV.3 blocks aggregation ( Figure 2A and Figure S2B ) and both dense and α-granule secretion ( Figure 2B , and not shown) to the five strains, whereas it had no effect on TRAP-induced activation. As FcγRIIA signals through Src and Syk tyrosine kinases, and consistent with a role for FcγRIIA, inhibitors of Src (dasatinib) or Syk (PRT-060318) also abrogated aggregation to all five strains ( Figure 2C and 2D, and Figure   S2C and S2D).
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
Bacteria-induced tyrosine phosphorylation of FcγRIIA is dependent on αIIbβ3
To further investigate the role of FcγRIIA in platelet activation by bacteria, we monitored tyrosine phosphorylation. Because of the high levels of plasma proteins, which mask tyrosine phosphorylation using standard extraction procedures, we used a method that involves removal of plasma proteins prior to cell lysis. We observed marked increase in tyrosine phosphorylation of FcγRIIA and its downstream signaling partners, Syk and PLCγ2, in platelets that had undergone aggregation in response to bacteria or to crosslinked mAb IV.3 ( Figure 3A 
Platelet activation by bacteria is also dependent on ADP and TxA 2
Platelet activation is reinforced by release of stored ADP from dense granules and de novo synthesis of TxA 2 . The P2Y 12 antagonist, cangrelor, and cyclooxygenase inhibitor, indomethacin, were used to investigate a role for the two feedback agonists in bacteriainduced platelet aggregation. Activation was inhibited to varying degrees in the presence of one of the two inhibitors (Figure 4 ), but with complete blockade observed in the presence of both inhibitors ( Figure 4 and Figure S3 ). In contrast, response to crosslinked mAb IV.3 was not affected, although de-aggregation was observed at later time points ( Figure S3 ). Thus, platelet activation by bacteria is also dependent on ADP and TxA 2 .
Human IgGs reconstitute aggregation to bacteria in washed platelets
Washed platelets were used to investigate the requirement for plasma components in aureus Newman, S. gordonii DL1 and S. oralis CR834 but not to S. sanguinis 133-79 was reduced when IgG was added together with fibrinogen, although on its own, fibrinogen alone was unable to restore aggregation to the four strains ( Figure 5 ). For S.
aureus Newman, IgG-depleted fibrinogen was used, as the presence of residual IgGs is sufficient to support aggregation to this strain ( 40 and not shown). We were unable to consistently restore aggregation to S. pneumoniae IO1196 in the presence of IgG and fibrinogen (aggregation was observed in two out of five donors after times greater than 15 min) suggesting that other plasma components might be required for robust
activation. These results demonstrate that IgG and fibrinogen are required to support bacteria-induced aggregation in washed platelets. Figure 6A , and not shown). Aggregation to S. aureus Newman in the transgenic platelets (including endogenous fibrinogen) was strictly dependent on human IgG and was blocked in the presence of the mouse αIIbβ3
antagonist lotrafiban and the Src kinase inhibitor dasatinib ( Figure 6B ).
Platelet factor 4 modulates bacteria-induced platelet aggregation
The platelet α-granule secreted chemokine PF4 has recently been proposed to have a critical role in the innate defense system by coating bacteria and binding to circulating Newman, the binding of PF4 in plasma was undetectable.
We then monitored the effect of PF4 on the lag time to activation. Addition of PF4 (20 μ g/mL) to washed platelets in the presence of IgG and fibrinogen reduced the time to onset of aggregation for the five strains ( Figure 7B ), although PF4 alone had no effect on its own (not shown).
For higher concentrations the effect was strain-specific, ranging from a reduction or increase in lag time, or abolition of response ( Figure 7C and Figure S4A ). Heparin had no effect on platelet aggregation either on its own or on TRAP-induced aggregation at any of the concentrations used in this study ( Figure S4B and S4C) . The dose dependency of the effect of heparin on platelet activation is similar to that seen in HIT serum, with low concentrations inducing activation and higher concentrations causing abolition of response.
α-granule deficient platelets do not respond to most bacteria
We used platelets from a patient with Grey Platelet Syndrome (GPS), who lacks platelet α-granules, to further investigate a possible role for PF4 in platelet activation to bacteria. Because GPS is associated with a mild thrombocytopenia, these studies were performed with a lower platelet count of 1x10 8 /ml, alongside a control with diluted plasma. While all strains induced robust aggregation in the control, only S. oralis CR834 induced aggregation of GPS platelets and this was blocked by mAb IV.3, confirming its dependency on FcγRIIA ( Figure 7D ). These data support a role for α-granule secretion in supporting platelet activation to four of the five strains.
For
Discussion
The five Gram-positive bacterial strains included in this study belong to different species and are known to interact with platelets using strain-specific interactions as outlined in the introduction. We have performed a systematic comparison of the five bacteria and found that they also share a common pathway of platelet activation that involves FcγRIIA activation of Src and Syk kinases and that this is reinforced by We propose that, after binding of bacteria to the platelet surface through a variety of strain-specific pathways, the initiating event in activation is engagement of . In this way, ClfA/B might engage a strong cooperation between these receptors. This could explain why this strain induces aggregation of FcγRIIA-transgenic mouse platelets, in which cooperation between the two receptors has been reported. 28 The absence of FcγRIIA-transgenic platelet aggregation to the other bacteria might be due to poor conservation of the strain-specific molecular interactions that are required to facilitate subsequent FcγRIIA-mediated activation. In summary, in this study we provide evidence that bacteria induce activation of platelets through strain-specific interactions and a common pathway that involves 
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